Top etanercept Articles in Internal Medicine

Pretreatment With the Tumor Nerosis Factor-[alpha] Blocker Etanercept Attenuated Ischemia-Reperfusion Renal Injury
Transplantation Proceedings, 11/18/2009

Choi DE et al. – Etanercept improved resistance to renal injury during IR by enhancing the activation of ERK and increasing the Bcl–2/Bax ratio. [more...]

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis
Rheumatology International, 10/27/2009

Giardina AR et al. – The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2–year ... more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated. [more...]

Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis
Dermatology, 10/23/2009

Reich K et al. – Patients with moderate–to–severe psoriasis entered this trial with serious PRO impairment. At week 12, etanercept 50 mg QW provided ... improvements compared with placebo. After 24 weeks of etanercept, the patients' serious PRO impairment had largely abated. [more...]

Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Cochrane Reviews, 10/12/2009

Singh JA et al. – Based upon indirect comparisons, anakinra seemed less efficacious than etanercept, adalimumab and rituximab and etanercept seemed to cause fewer withdrawals due to adverse events than adalimumab, anakinra and infliximab. Significant heterogeneity in [more...]

Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO Study
Zeitschrift für Rheumatologie, 10/07/2009

Schulze–Koops H et al. – The TEMPO study has shown that the combination of etanercept and methotrexat (MTX) in the treatment of rheumatoid arthritis (RA) is superior to [more...]

Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis
Scandinavian Journal of Rheumatology, 11/19/2009

Klimiuk PA et al. – The study shows that, besides a rapid suppression of disease activity, serum sCAM and ... concentrations are downregulated following anti–tumour necrosis factor alpha therapy combined with MTX. Prolonged treatment with etanercept sustained or even more remarkably diminished the sCAM and VEGF serum concentrations. [more...]

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study
Journal of the European Academy of Dermatology and Venereology, 11/18/2009

Dauden E et al. – At baseline, patients exhibited significant quality–of–life impairment. Both continuous and paused etanercept treatment provided improvements in PRO measures. Either [more...]

Early subcutaneous administration of etanercept (ENBREL) prevents from hyperoxia-induced lung injury
Experimental Lung Research, 11/09/2009

Guthmann F et al. – The authors assume that subcutaneous administration of etanercept might be suitable to prevent acute lung injury and its sequelae induced by hyperoxic ventilation of [more...]

Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis
Modern Rheumatology, 11/19/2009

Tsujimura S et al. – Etanercept is useful for overcoming P-gp-mediated treatment resistance in intractable RA patients who have to discontinue infliximab or are intolerant ... CD69. Incubation of these lymphocytes with dexamethasone in vitro reduced intracellular dexamethasone levels. Two-week etanercept therapy significantly reduced P-gp expression and eliminated such P-gp- and CD69-high-expressing subgroup. The reduction in P-gp resulted in [more...]

Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/2009

receiving adalimumab or infliximab had higher risk than those treated with etanercept: SIR = 4.1 (2.3–7.1) and 3.6 (2.3–5.6) versus 0.9 (0.4–1.8) Exposure to adalimumab or infliximab versus etanercept independent risk factor for lymphoma in case-control study: odds ratio=4.7 (1.3–17.7) and [more...]